| Monitoring and treatment of MDS in genetically susceptible persons |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Genetic predisposition to MDS: diagnosis and management |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome |
|
Hematology. American Society of Hematology. Education Program |
Aplastic Anemia |
| Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?: Considering the Results of the Medicare Coverage With Evidence Development Study |
|
JAMA Oncology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party |
|
Bone Marrow Transplantation |
Aplastic Anemia |
| Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study |
|
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
|
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
| Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
